Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

775 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I study of once weekly treatment with bortezomib in combination with lenalidomide and dexamethasone for relapsed or refractory multiple myeloma.
Totani H, Ri M, Kato C, Nakashima T, Suzuki N, Hagiwara S, Kanamori T, Murakami S, Masuda A, Kinoshita S, Yoshida T, Narita T, Ito A, Kusumoto S, Ishida T, Komatsu H, Iida S. Totani H, et al. Among authors: narita t. Int J Hematol. 2016 Mar;103(3):316-21. doi: 10.1007/s12185-015-1925-7. Epub 2015 Dec 29. Int J Hematol. 2016. PMID: 26715148 Clinical Trial.
Cyclin-dependent kinase 9 as a potential specific molecular target in NK-cell leukemia/lymphoma.
Kinoshita S, Ishida T, Ito A, Narita T, Masaki A, Suzuki S, Yoshida T, Ri M, Kusumoto S, Komatsu H, Shimizu N, Inagaki H, Kuroda T, Scholz A, Ueda R, Sanda T, Iida S. Kinoshita S, et al. Among authors: narita t. Haematologica. 2018 Dec;103(12):2059-2068. doi: 10.3324/haematol.2018.191395. Epub 2018 Aug 3. Haematologica. 2018. PMID: 30076184 Free PMC article.
Impact of chromosomal abnormalities on the efficacy of lenalidomide plus dexamethasone treatment in patients with relapsed/refractory multiple myeloma.
Yoshida T, Ri M, Fujinami H, Oshima Y, Tachita T, Marumo Y, Sasaki H, Kinoshita S, Totani H, Narita T, Masaki A, Ito A, Kusumoto S, Ishida T, Komatsu H, Iida S. Yoshida T, et al. Among authors: narita t. Int J Hematol. 2019 Aug;110(2):228-236. doi: 10.1007/s12185-019-02669-z. Epub 2019 May 22. Int J Hematol. 2019. PMID: 31119611
Tax is a potential molecular target for immunotherapy of adult T-cell leukemia/lymphoma.
Suzuki S, Masaki A, Ishida T, Ito A, Mori F, Sato F, Narita T, Ri M, Kusumoto S, Komatsu H, Fukumori Y, Nishikawa H, Tanaka Y, Niimi A, Inagaki H, Iida S, Ueda R. Suzuki S, et al. Among authors: narita t. Cancer Sci. 2012 Oct;103(10):1764-73. doi: 10.1111/j.1349-7006.2012.02371.x. Epub 2012 Aug 13. Cancer Sci. 2012. PMID: 22735080 Free PMC article.
Angioimmunoblastic T-cell lymphoma mice model.
Sato F, Ishida T, Ito A, Mori F, Masaki A, Takino H, Narita T, Ri M, Kusumoto S, Suzuki S, Komatsu H, Niimi A, Ueda R, Inagaki H, Iida S. Sato F, et al. Among authors: narita t. Leuk Res. 2013 Jan;37(1):21-7. doi: 10.1016/j.leukres.2012.09.009. Epub 2012 Sep 29. Leuk Res. 2013. PMID: 23026775
775 results